The Single Secret That Will Pave the Way to Biotech Wealth

Saturday November 6, 2010 Join Money Morning on Facebook| Twitter| RSS Feed | The Single Secret That Will Pave the Way to Biotech Wealth Dear Money Morning Reader, In the last part of a career as a newspaper journalist that spanned more than two decades, and that saw me cover just about every major business sector, I spent three years covering the biotech sector. It was a real eye-opener. The drug-development process was Byzantine. And the failure rate was frustratingly high. In the end, however, I realized that it was time well spent. Not only did I gain a working knowledge of a key industry of the future, I also learned the industry's key secret - the single pathway to biotech riches. During that three-year stretch, I heard about many new ideas. I saw the results of many clinical trials. I saw a few companies unveil new drugs or therapies. And several times I saw one company - eager to cash in - buy out another. But here's what I never saw: During that three-year span, never once did I see one drug make it from drawing board to FDA approval and to the marketplace. By some estimates, it takes 10 years and $500 million to more than $1 billion to develop a new drug. And with good reason: The research - especially involving genetics - is fearfully expensive. The regulatory hurdles that must be cleared are almost impossible for an industry outsider to imagine. A drug can spend five years in a research lab before human testing begins. And even then questionable results from a single trial can send the drug-development team back to the research lab - or can kill the project right where it stands. Out of every 1,000 drug "compounds" that enter lab testing, only one makes it to human testing. And even then the many required FDA approvals create a long-and-risky path for new-drug development. And yet, the payoff from a winner is huge - if you know the secret. And here it is.... The best time to invest is just before approval, when the uncertainty is minimized - but before the media drumbeat turns the discovery into a household name. Unfortunately, the average investor usually lacks the time and the resources to ferret out such truly promising situations. But that's okay: With this profit opportunity, we've done that heavy lifting for you. In a new report, "New 'Smart Drug' Unleashes Holy Hell on Nature's Deadliest Disease," we detail a company that has created a new cancer treatment that's more effective than anything on the market today. The new "smart drug" technology - we call it "programmed cell destruction," or PCD - is said to work in four out of five patients, including some on whom other therapies have failed. PCD was developed based on research done by the vaunted Human Genome Project, but has yet to reach the mainstream news media. In fact, the shares of this particular company were trading at only $7 a share recently. If you'd like to find out more about this opportunity, I'd urge you to click here and take a look at our new report. It'll only take you a few minutes to read it and decide from there. In my book, that's a much better use of your time than having to wait 10 years for a payoff. Sincerely; William (Bill) Patalon III Executive Editor Money Morning Tiny Maryland Company About to Unleash Holy Hell... Thanks to recent advances in genetics, this company has created "warrior" cells that crush nature's deadliest disease. Forbes Science Business calls it: "The wave of the future." Estimates show the potential market for this breakthrough could be $7.5 billion! Enough to shoot this little stock from $7 to $140. Our full report is just now complete. Go here. Money Morning : You are receiving this e-mail as a part of your free subscription to The Money Morning E-Letter . Remove your email from this list: Unsubscribe To cancel by mail or for any other subscription issues, write us at: Money Morning Attn: Member Services 105 West Monument Street Baltimore, MD 21201 2010 Money Money Morning 105 West Monument Street Baltimore, MD 21201 North America: 1 888 384 8339; Fax: 1 410 223 2650 International: +1 410 230 1200 ; Fax: +1 410 223 2650 Website: http://www.moneymorning.com Nothing in this e-mail should be considered personalized advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning. 105 W. Monument Street, Baltimore MD 21201.